The past, present, and future of liver cancer research in China

Anwanwan, 2020, Challenges in liver cancer and possible treatment approaches, Biochimica et biophysica acta, Rev. Cancer, 1873 Cao, 2022, Long term outcome of prevention of liver cancer by hepatitis B vaccine: results from an RCT with 37 years, Cancer Lett., 536, 10.1016/j.canlet.2022.215652 Rumgay, 2022, Global burden of primary liver cancer in 2020 and predictions to 2040, J. Hepatol., 77, 1598, 10.1016/j.jhep.2022.08.021 Xia, 2022, Cancer statistics in China and United States, 2022: profiles, trends, and determinants, Chin. Med. J., 135, 584, 10.1097/CM9.0000000000002108 Cao, 2020, Disease burden of liver cancer in China: an updated and integrated analysis on multi-data source evidence, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, 41, 1848 Momin, 2018, Promising practices for the prevention of liver cancer: a review of the literature and cancer plan activities in the National Comprehensive Cancer Control Program, CCC (Cancer Causes Control), 29, 1265, 10.1007/s10552-018-1094-0 Chang, 2020, Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma, Int. J. Mol. Sci., 21, 10.3390/ijms21218165 Jing, 2021, Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver cancer to systemic therapy, Cancer Lett., 519, 46, 10.1016/j.canlet.2021.06.016 Liu, 2022, Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma, Cancer Lett., 536, 10.1016/j.canlet.2022.215642 Ren, 2022, PDE4D binds and interacts with YAP to cooperatively promote HCC progression, Cancer Lett., 541, 10.1016/j.canlet.2022.215749 Wu, 2022, Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis, Cancer Lett., 525, 115, 10.1016/j.canlet.2021.10.039 Xu, 2022, Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity, Cancer Lett., 548, 10.1016/j.canlet.2022.215898 Zhang, 2022, DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma, Cancer Lett., 548, 10.1016/j.canlet.2022.215899 Chen, 2006, CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature, J. Am. Soc. Inf. Sci. Technol., 57, 359, 10.1002/asi.20317 van Eck, 2010, Software survey: VOSviewer, a computer program for bibliometric mapping, Scientometrics, 84, 523, 10.1007/s11192-009-0146-3 Shi, 2021, Is it possible to halve the incidence of liver cancer in China by 2050?, Int. J. Cancer, 148, 1051, 10.1002/ijc.33313 Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet (London, England), 391, 1163, 10.1016/S0140-6736(18)30207-1 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N. Engl. J. Med., 359, 378, 10.1056/NEJMoa0708857 Cheng, 2022, Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma, J. Hepatol., 76, 862, 10.1016/j.jhep.2021.11.030 Lin, 2022, Identification of three key genes associated with hepatocellular carcinoma progression based on Co-expression, Analysis, 80, 301 Lin, 2022, Nucleoporin 93 mediates β-catenin nuclear import to promote hepatocellular carcinoma progression and metastasis, Cancer Lett., 526, 236, 10.1016/j.canlet.2021.11.001 Li, 2022, Letter to the editor regarding "The E2F1/USP11 positive feedback loop promotes hepatocellular carcinoma metastasis and inhibits autophagy by activating ERK/mTOR pathway", Cancer Lett., 527, 26, 10.1016/j.canlet.2021.12.004 Li, 2016, PCAF inhibits hepatocellular carcinoma metastasis by inhibition of epithelial-mesenchymal transition by targeting Gli-1, Cancer Lett., 375, 190, 10.1016/j.canlet.2016.02.053 Yeung, 2022, TEC kinase stabilizes PLK4 to promote liver cancer metastasis, Cancer Lett., 524, 70, 10.1016/j.canlet.2021.08.038 Yuan, 2022, The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition, Cancer Lett., 549, 10.1016/j.canlet.2022.215921 Chen, 2018, LncTIC1 interacts with β-catenin to drive liver TIC self-renewal and liver tumorigenesis, Cancer Lett., 430, 88, 10.1016/j.canlet.2018.05.023 Huang, 2018, Corrigendum to "LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis", Cancer Lett., 10.1016/j.canlet.2018.08.024 Liu, 2022, SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback, Cancer Lett., 528, 16, 10.1016/j.canlet.2021.12.026 Liang, 2022, Letter to the editor regarding "An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells.", Cancer Lett., 539, 10.1016/j.canlet.2022.215602 Wang, 2022, Inhibition of Arid1a increases stem/progenitor cell-like properties of liver cancer, Cancer Lett., 546, 10.1016/j.canlet.2022.215869 Pang, 2021, Plasmacytoid dendritic cells recruited by HIF-1α/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma, Cancer Lett., 522, 80, 10.1016/j.canlet.2021.09.022 Wan, 2022, MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy, Cancer Lett., 541, 10.1016/j.canlet.2022.215750 Dai, 2022, Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma, Cancer Lett., 524, 161, 10.1016/j.canlet.2021.10.024